Statin use and vitreoretinal surgery : Findings from a Finnish population-based cohort study

Show full item record



Permalink

http://hdl.handle.net/10138/305624

Citation

Loukovaara , S , Sahanne , S , Takala , A & Haukka , J 2018 , ' Statin use and vitreoretinal surgery : Findings from a Finnish population-based cohort study ' , Acta Ophthalmologica , vol. 96 , no. 5 , pp. 442-451 . https://doi.org/10.1111/aos.13641

Title: Statin use and vitreoretinal surgery : Findings from a Finnish population-based cohort study
Author: Loukovaara, Sirpa; Sahanne, Sari; Takala, Annika; Haukka, Jari
Contributor: University of Helsinki, INDIVIDRUG - Individualized Drug Therapy
University of Helsinki, Clinicum
University of Helsinki, Anestesiologian yksikkö
University of Helsinki, Clinicum
Date: 2018-08
Language: eng
Number of pages: 10
Belongs to series: Acta Ophthalmologica
ISSN: 1755-375X
URI: http://hdl.handle.net/10138/305624
Abstract: PurposeVitreoretinal (VR) surgery is the third most common intraocular surgery after refractive and cataract surgery. The impact of statin therapy on VR surgery outcomes remains unclear, despite a potentially beneficial effect. We explored the association of preoperative statin therapy and the need for revitrectomy after primary vitrectomy. MethodsOur historical, population-based, register-based, VR surgery cohort consisted of 5709 patients operated in a tertiary, academic referral hospital in Finland, during 2008-2014, covering 6.5years. Subgroup analysis was performed as follows: eyes operated due to (i) rhegmatogenous retinal detachment (RRD), (ii) VR interface diseases (macular pucker/hole), (iii) diabetic maculopathy or proliferative retinopathy, (iv) vitreous haemorrhage, (v) lens subluxation, (vi) vitreous opacities or (vii) other VR indication. The primary end-point event was revitrectomy during a postoperative follow-up period of 1year due to retinal redetachment, vitreous rehaemorrhage, postoperative endophthalmitis, recurrent pucker or unclosed macular hole. ResultsRhegmatogenous retinal detachment (RRD) was the second most frequent indication of VR surgery, including 1916 patients, with 305 re-operations with rate 0.20 (95% CI 0.18-0.23) per person-year. Statin treatment in time of operation was associated with lower risk of re-operation according to relative scale (incidence rate ratio 0.72, 95% CI 0.53-0.97), but not in absolute scale (incidence rate difference -0.58, 95% CI -4.30 to 3.15 for 100 person-years). No association with statin therapy and vitrectomy outcome was observed in the other VR subgroups. ConclusionUse of statin treatment was associated with a 28% lower risk of revitrectomy in patients operated due to RRD. Further randomized clinical trials are highly warranted.
Subject: cohort study
epidemiology
proliferative vitreoretinopathy
rhegmatogenous retinal detachment
statin therapy
vitreoretinal surgery
RHEGMATOGENOUS RETINAL-DETACHMENT
LOW INTRAVITREAL ANGIOPOIETIN-2
PARS-PLANA VITRECTOMY
PROLIFERATIVE VITREORETINOPATHY
ANTICOAGULANT-THERAPY
DIABETIC-PATIENTS
MANAGEMENT
DISEASES
OUTCOMES
METAANALYSIS
3125 Otorhinolaryngology, ophthalmology
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
Statin_use_and_vitreoretinal_surgery.pdf 408.8Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record